Socid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Socid

Property Description
Active ingredient Omeprazole (INN)
Form Capsule (Oral, Delayed-Release)
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained Gastric Acid Suppression
Origin Synthetic (Substituted Benzimidazole)
Availability Typically Prescription-Only (Rx)

What is Socid and its Pharmacological Class?

Socid is a synthetic, single-ingredient medicine classified as a Proton pump inhibitor (PPI), containing the active chemical substance Omeprazole (INN). This compound belongs to the family of substituted benzimidazoles, representing a foundational member of its pharmacological class. The regulatory profile confirms this classification, establishing it as an essential medicine for controlling stomach acidity.

Socid's identity as a PPI is central to its function, establishing it as a type of anti-ulcer agent designed specifically to address issues caused by excessive gastric acid. While the active ingredient Omeprazole is widely available, Socid is often positioned as a prescription-only (Rx) product, differentiating it from lower-dose, over-the-counter (OTC) forms used for general frequent heartburn.


Composition and Physical Form

The core of Socid's composition is its active ingredient, Omeprazole, typically delivered in an oral preparation formulated as a capsule. These capsules are engineered for delayed release and contain essential pharmaceutical excipients that stabilize the medication.

The design of the capsule is crucial because Omeprazole is highly sensitive to acid. The gastro-resistant coating ensures the compound passes safely through the highly acidic environment of the stomach and is released only when it reaches the less acidic environment of the small intestine. This targeted delivery allows the active ingredient to be properly absorbed into the bloodstream, maximizing its reliable performance.


General Purpose: How it Reduces Gastric Acidity

The general purpose of Socid is to achieve comprehensive and sustained gastric acid suppression to promote healing and provide relief from acid-related discomfort. It accomplishes this by a direct action on the parietal cells in the stomach lining.

The medication functions by irreversibly inhibiting the H^+/K^+-ATPase enzyme system, known as the proton pump. By effectively blocking this final step in the acid-secreting pathway, Socid significantly lowers the overall acidity in the stomach. This reduced acidity is the core action by which the medicine generally helps relieve symptoms and allows the irritated or eroded tissues of the upper digestive lining to recover.

Regulatory References

  1. Omeprazole on the WHO Essential Medicines List

What side effects are possible with Socid?

Possible Side Effects and Safety Information

The official safety documentation for Socid (Omeprazole) outlines adverse reactions based on their frequency and the physiological systems affected. This framework helps distinguish between common, expected effects and rare, clinically significant events, as defined by regulatory bodies.


Documented Adverse Reactions

The most frequently reported effects listed as Common in regulatory documents include headache and gastrointestinal issues such as abdominal pain, nausea, vomiting, diarrhea, and flatulence. Uncommon reactions may involve the nervous system (dizziness, vertigo, paresthesia), skin (rash, pruritus), and general symptoms (malaise, peripheral oedema). Reactions classified as Rare or Very Rare include more severe effects on the blood (leukopenia), immune system (hypersensitivity reactions), and liver (hepatitis).


Serious Safety Considerations and Long-Term Patterns

Official prescribing information highlights specific safety concerns, often linked to long-term exposure or use at high doses. These include an increased risk of bone fractures of the hip, wrist, or spine, and nutrient deficiencies like Hypomagnesemia (low magnesium) and Vitamin B12 deficiency, typically documented after prolonged therapy. Regulatory documents also cite rare but serious events such as severe cutaneous adverse reactions (e.g., Stevens-Johnson Syndrome) and Acute Interstitial Nephritis (a form of kidney inflammation).


Regulatory Safety Notes

Specific limitations noted in official labeling include a contraindication for individuals with known hypersensitivity to omeprazole or other benzimidazoles. Furthermore, a regulatory constraint requires the exclusion of gastric malignancy, as symptomatic relief from the medicine does not rule out the presence of a tumor. The drug's effect on stomach acid can also impact the absorption of certain other pH-dependent medications.

Overdose and Emergency Response

Socid Overdose and when to seek help

The official regulatory documentation for Socid (Omeprazole) overdosage describes a clinical profile where symptoms are typically transient. Manifestations generally affect the central nervous system, including drowsiness, confusion, and headache. Additional signs may involve blurred vision, nausea, vomiting, tachycardia (increased heart rate), flushing, and increased sweating. Overdoses have been reported across a wide range of doses, yet toxic ingestion is frequently noted to result in no serious clinical outcome.

Regulatory guidance mandates specific, immediate actions upon suspected overexposure. The requirement is to seek immediate medical attention and contact a Poison Help line. Urgent escalation is necessary for defined life-threatening events: Call emergency services immediately if the individual has a seizure (convulsions), collapse, or severe trouble breathing.

The established treatment principle is symptomatic and supportive treatment due to an official statement that no specific antidote is known. The drug is also reported to be extensively protein bound, meaning it is not readily dialyzable. This limits procedural interventions and defines the required supportive approach to managing the overdose presentation.

Therapeutic Uses of Socid

Quick Facts

  • Target Condition: Supports individuals managing symptoms of Major Depressive Disorder (MDD).
  • Secondary Use: May be used as a component of care for Generalized Anxiety Disorder (GAD).
  • Core Role: A therapeutic option to help stabilize mood and promote overall well-being.

What Socid Treats: Main Uses and Benefits

Socid is an established prescription medication used to address various mental health conditions. Its primary therapeutic domain is the management of Major Depressive Disorder (MDD). For individuals experiencing persistent periods of low mood and loss of interest, Socid may help alleviate symptoms and contribute to a more stable emotional state.

The medication is also utilized as a supportive measure in the comprehensive treatment of Generalized Anxiety Disorder (GAD). In this context, it may assist in moderating excessive worry and associated tension. Utilizing Socid is intended to support the patient's existing care plan, promoting functional improvement and enhancing the ability to engage in daily life. This approach is intended to manage disease progression and mitigate challenges related to the condition.

Socid is one of the therapeutic options utilized for these indications.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Socid? (Omeprazole)

Official regulatory documents define strict population eligibility for Socid (Omeprazole) based on patient characteristics and co-existing conditions, not clinical preference.

Contraindications and Restrictions

Absolute Contraindications: Socid is strictly prohibited for patients with known hypersensitivity to the active ingredient, any component of the formulation, or to substituted benzimidazoles. Use is also contraindicated when taking certain antiviral medications such as nelfinavir or rilpivirine-containing products.

Age and Condition Restrictions: Safety and effectiveness are not established for pediatric patients under 1 year of age. Use is not recommended for women who are nursing/breastfeeding, requiring the cessation of either the medication or nursing. Patients with impaired hepatic function may require conditional use and reduced dosing, whereas those with renal impairment generally do not.

Eligible Populations

Socid is approved for use in adults and in pediatric patients starting from 1 year of age for specific labeled indications. The drug's eligibility profile requires caution and screening for conditions such as gastric malignancy prior to initiation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Socid (Omeprazole) is defined by its pharmacokinetic effects, primarily potent CYP2C19 inhibition and significant gastric pH modulation.

Interaction Classifications and Restrictions

The regulatory labeling designates certain combinations as strictly prohibited or restricted based on the risk of altered drug exposure.

  • Contraindicated Combinations: Co-administration with Rilpivirine-containing products is formally contraindicated by the FDA, as it significantly reduces Rilpivirine plasma levels, risking loss of therapeutic effect.
  • Exposure Reduction (pH-Dependent): The pH increase caused by Socid reduces the absorption of drugs that require an acidic environment, such as the antivirals Atazanavir and Nelfinavir, and antifungals like Ketoconazole, potentially leading to therapeutic failure.
  • Exposure Increase (Enzyme Inhibition): Socid's inhibition of CYP2 C19 reduces the clearance of drugs like Diazepam, Phenytoin, and Cilostazol, resulting in increased plasma concentrations.
  • Antiplatelet Restriction: Omeprazole reduces the formation of the active metabolite of Clopidogrel, which officially leads to diminished anti-platelet activity.

Timing and Substance Interactions

Specific substances are noted for concentration-altering effects, and certain procedures require separation. For instance, St John’s Wort and Rifampin are documented to reduce Omeprazole concentrations. Additionally, a temporary cessation of at least 14 days is required before specific diagnostic tests, such as Chromogranin A ( CgA) level assessment.

Mechanism of Action

Socid (Omeprazole) exerts its action via a specific, peripheral mechanism that targets the machinery of acid production within the stomach lining.


Irreversible Blockade of the H^+/ K^+-ATPase

The drug's primary action is the irreversible inhibition of the Proton Pump ( H^+/ K^+-ATPase) enzyme system found in the parietal cells. This enzyme is the terminal molecular target responsible for secreting hydrogen ions ( H^+) to form acid, which means the mechanism blocks the final common pathway for all acid stimulation. The physiological consequence is a sustained reduction in the concentration of H^+ ions within the gastric lumen.


Acid-Dependent Activation and Sustained Effect

Omeprazole is a prodrug that must first be chemically converted into its active form (a sulfenamide) by the highly acidic environment near the pump; this step ensures the molecule is selectively activated at the site of action. Because the active form creates a covalent bond with the enzyme, the suppression of acid secretion is maintained until new pump units are synthesized and inserted into the cell membrane, which dictates the extended duration of pH elevation.

Dosage and Administration Information

How Socid is Used: Official Administration Guidelines

The use of Socid (Omeprazole) follows explicit instructions outlined in official documentation, defining the routes, schedules, and conditions for its administration. This structure ensures adherence to the designated protocol.

Instruction Category Regulatory-Stated Rule
Route and Timing The standard route is Oral (PO). It must be taken at least one hour before a meal, typically in the morning, for optimal suppression of acid secretion.
Dosing Schedule The standard adult dose is often 20 mg once daily. Doses for specific conditions may range higher, with total daily doses exceeding 80 mg requiring administration in divided doses.
Administration Conditions The delayed-release capsule must be swallowed whole; it is a critical procedural condition that it must not be crushed, chewed, or opened. Intravenous (IV) use is restricted to when oral intake is temporarily not possible.
Dose Modification A dose reduction is officially specified for patients with hepatic impairment, with 10 mg to 20 mg once daily often being sufficient. No adjustment is required for renal impairment, and pediatric dosing is weight-based.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; do not take a double dose.

Resulting Procedural Structure

The official instructions establish the relationship between timing and food intake to ensure optimal drug action. These rules define the length of therapy as either short-term (e.g., 4 to 8 weeks) or long-term for maintenance regimens, providing a clear framework for the use protocol as established by regulatory authorities.

Recent Clinical Evidence

Research evidence / Overview of Studies for Socid (Omeprazole)

Research into the Association with Depressive Symptoms

Socid (Omeprazole) was studied for associations with mood in research exploring how symptoms change over time. Large-scale population-based cohort studies were observed in adults and older adults to examine the statistical relationship between continuous use of this class of medicine and the later diagnosis of depression. These studies compared the frequency of a new depression diagnosis between users and non-users of the medicine. Analyses of post-marketing surveillance data also reported measurements of related adverse events.

These studies report how symptoms evolved in the observed populations, describing patterns suggesting an association with the diagnosis of major depressive disorder (MDD) in some populations. Long-term effects are not fully established regarding this association. A lack of large-scale Randomized Controlled Trials (RCTs) specifically designed to track mental health outcomes means the evidence is primarily derived from settings with varying symptom burdens. The observed research is ongoing, and the potential influence of the original health condition that required treatment remains uncertain and can affect the findings (confounding).

Research into the Association with Anxiety Symptoms

Research has also explored the relationship between the use of Omeprazole and anxiety disorders. Epidemiological studies and population-based cohort studies were observed in adults and children to examine the statistical correlation between taking the medication and the subsequent diagnosis of anxiety. The patterns observed in human cohort studies were compared with preclinical data that measured specific alterations in anxiety-related behaviors in laboratory settings.

Evidence is limited for long-term tracking of anxiety symptoms in human populations taking this medicine. Subgroup findings are uncertain, meaning that the evidence quality varies across studies. Research is ongoing to provide context and reduce the reliance on observational data, particularly to address the potential for confounding by indication.

Frequently Asked Questions (FAQ)

Common questions about Socid (FAQ)


Q: What is the main reason doctors prescribe Socid?

A: Official regulatory documents state that Omeprazole (Socid) is indicated for treating several conditions where the stomach produces too much acid. This includes healing active duodenal and gastric ulcers, treating symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis, and, in combination with antibiotics, eliminating H. pylori bacteria.

Q: Is Socid used for more than one medical condition?

A: Yes. Omeprazole (Socid) is indicated for multiple medical conditions. These include duodenal ulcers, gastric ulcers, the eradication of H. pylori, symptomatic GERD, erosive esophagitis, and pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Q: Why is Socid only available by prescription?

A: Omeprazole (Socid) is actually available in both prescription and over-the-counter (OTC) forms. The prescription strength and formulation is used to treat more severe conditions like erosive esophagitis, while the lower-dose OTC version is used specifically for the short-term treatment of frequent heartburn.

Q: Does Socid come in different forms, like a tablet or liquid?

A: Yes. Official information on Omeprazole (Socid) indicates that it is available in several forms to suit patient needs, including delayed-release capsules, delayed-release tablets, and delayed-release oral suspension packets.


Q: How quickly should I expect Socid to start working?

A: The medication begins to reduce stomach acid production within one hour of the first dose. Full therapeutic benefit, such as symptom relief, is generally expected to develop over 1 to 4 days of continued, daily administration.

Q: How long does the effect of one dose of Socid last?

A: The duration of the acid-inhibitory effect of a single dose lasts for an extended period, up to 72 hours (3 days). This long duration of effect is a result of the drug's intended action.

Q: Do I need to take Socid at the same time every day?

A: The recommended dosage for Omeprazole (Socid) for most conditions is typically administered once daily. To help maintain consistent effect, official information on daily dosing implies the need for a regular schedule.

Q: Are there any specific foods or drinks that should be avoided while taking Socid?

A: Regulatory information advises that the medication should be taken before eating for optimal absorption. While the label focuses on timing relative to food, it does not list specific foods or drinks to avoid entirely.


Q: Can a person stop taking Socid suddenly?

A: Regulatory advisories note that discontinuation, particularly after long-term therapy, is associated with the potential for rebound acid hypersecretion, a temporary return or worsening of acid reflux symptoms.

Q: Does Socid have any known impact on driving ability?

A: Official patient information states that Omeprazole (Socid) generally does not affect the ability to drive or operate machinery. If a patient experiences dizziness or problems with vision, activities requiring alertness, such as driving or operating machinery, should be avoided.

Q: What information is available about Socid and its impact on vision?

A: Visual disturbances, including general problems with vision, have been reported as potential side effects in the official information. Official warnings note that if vision problems occur, driving or operating machinery should be avoided.

Q: Is it common to feel tired after starting Socid?

A: Fatigue and excessive tiredness have been reported as potential effects. Additionally, very long-term use is associated with deficiencies in Vitamin B12, which can contribute to tiredness.

Q: Is it normal to experience a dry mouth when taking Socid?

A: While it is not one of the most frequently reported side effects, dry mouth is documented in the overall adverse reaction data for Omeprazole, meaning it is a known potential effect.

Q: Does taking Socid require regular blood tests?

A: The official label does not mandate routine blood tests for all patients. However, long-term use has been associated with deficiencies in certain nutrients (like Vitamin B12 and Magnesium). Official advisories note that monitoring of these levels may be considered, particularly for patients on long-term therapy.

Q: Does Socid interact with common over-the-counter pain relievers?

A: Official prescribing information addresses numerous drug interactions, but does not list common OTC pain relievers (like ibuprofen or acetaminophen) as being directly contraindicated or requiring a dose change.


Q: Are there any official recommendations regarding using Socid during pregnancy?

A: Official labeling advises that Omeprazole (Socid) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Epidemiologic studies of use during pregnancy are unlikely to show a major risk of malformation.

Q: What does the patient information leaflet say about Socid and fertility?

A: Animal studies, primarily at high doses, have shown some evidence of toxicities that affected the developing fetus. These potential effects underscore the importance of discussing treatment with a healthcare provider, especially for individuals who are pregnant, planning to conceive, or have fertility concerns.

Q: Is Socid a controlled substance?

A: No. Omeprazole (Socid) is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or other major government scheduling authorities.

How should Socid be stored and disposed of?

How to Store and Dispose of Socid (Omeprazole)

The official storage requirements for Socid (Omeprazole Delayed-Release Capsules) are established to protect the active ingredient from degradation caused by heat, light, and moisture.

Storage Conditions and Integrity

  • The medicine must be stored at a temperature not exceeding 30 C and kept in a dry place.
  • The capsules must be protected from light and moisture by storing them in the original container and keeping the container tightly closed.
  • If stored in a bottle, the product has a mandated in-use shelf life of 100 days after first opening.

Disposal and Child Safety

  • The product must be kept out of the sight and reach of children.
  • Unused or expired product must be disposed of in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Socid found in:

A-Z Index: